NR4A1 and breast carcinoma: No significant difference in OS was observed for patients with either hormone receptor-positive (adjusted HR = 0.64, 95% CI 0.39–1.05; Fig. 2d) or negative (adjusted HR = 0.80, 95% CI 0.40–1.56; Fig. 3d) breast cancer (Pinteraction = 0.62; Supplementary Table 7).